Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole

Citation
M. Koc et al., Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole, AM J KIDNEY, 36(3), 2000, pp. NIL_59-NIL_64
Citations number
30
Categorie Soggetti
Urology & Nephrology
Journal title
AMERICAN JOURNAL OF KIDNEY DISEASES
ISSN journal
02726386 → ACNP
Volume
36
Issue
3
Year of publication
2000
Pages
NIL_59 - NIL_64
Database
ISI
SICI code
0272-6386(200009)36:3<NIL_59:SHITRT>2.0.ZU;2-Z
Abstract
Hyperkalemia is a serious electrolyte disorder and is a frequent finding in renal transplant recipients. Trimethoprim-induced hyperkalemia has been in creasingly reported in recent years. We describe two renal transplant recip ients who developed end-stage renal disease secondary to familial Mediterra nean fever and presented with severe hyperkalemia secondary to the use of s tandard dose of trimethoprim. One of the patients had potential underlying adrenal insufficiency, which might be a contributing factor for the develop ment of hyperkalemia. We concluded that renal transplant patients receiving even the standard dose of trimethoprim should be monitored closely for the development of hyperkalemia. They should be recognized as a group with inc reased risk In regard to their concurrent renal insufficiency, concomitant use of cyclosporine, and associated tubulointerstitial disease. Patients wi th secondary amyloidosis are at even greater risk, and subclinical adrenal insufficiency may be an underlying risk factor for the development of sever e, life-threatening hyperkalemia among this group of patients. (C) 2000 by the National Kidney Foundation, Inc.